Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the System...

por Keskin, Havva, Cadirci, Kenan, Demirkazik, Ahmet, Akbulut, Hakan, Yalcin, Bulent
Publicado 2019

Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer

por Demirkazik, Ahmet, Akbulut, Hakan, Ulger, A. Fusun, Arican, Ali, Ozer, Ismail, Acıkgoz, Nalan, Icli, Fikri
Publicado 2004

Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

por Dogan, Izzet, Gurbuz, Mustafa, Paksoy, Nail, Ferhatoglu, Ferhat, Vatansever, Sezai, Saip, Pinar, Demirkazik, Ahmet, Aydiner, Adnan
Publicado 2022

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, mult...

por Markóczy, Zsolt, Sárosi, Veronika, Kudaba, Iveta, Gálffy, Gabriella, Turay, Ülkü Yilmaz, Demirkazik, Ahmet, Purkalne, Gunta, Somfay, Attila, Pápai-Székely, Zsolt, Rásó, Erzsébet, Ostoros, Gyula
Publicado 2018

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

por Gürbüz, Mustafa, Kiliçkap, Saadettin, Bilici, Ahmet, Karadurmuş, Nuri, Sezer, Ahmet, Şendur, Mehmet Ali Nahit, Paydaş, Semra, Artaç, Mehmet, Fulden Yumuk, Perran, Gürsoy, Pinar, Uysal, Mükremin, Şenol Coşkun, Hasan, Tatli, Ali Murat, Selçukbiricik, Fatih, Dişel, Umut, Köksoy, Elif Berna, Güven, Deniz Can, Uğrakli, Muzaffer, Akkuş, Erman, Yücel, Şebnem, Erol, Cihan, Karakaya, Serdar, Şakalar, Teoman, Khanmammadov, Nijat, Paksoy, Nail, Demirkazik, Ahmet
Publicado 2022